JP2023081949A5 - - Google Patents

Download PDF

Info

Publication number
JP2023081949A5
JP2023081949A5 JP2023032695A JP2023032695A JP2023081949A5 JP 2023081949 A5 JP2023081949 A5 JP 2023081949A5 JP 2023032695 A JP2023032695 A JP 2023032695A JP 2023032695 A JP2023032695 A JP 2023032695A JP 2023081949 A5 JP2023081949 A5 JP 2023081949A5
Authority
JP
Japan
Prior art keywords
sequence
amino acid
tcr
acid residues
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023032695A
Other languages
English (en)
Japanese (ja)
Other versions
JP7577149B2 (ja
JP2023081949A (ja
Filing date
Publication date
Priority claimed from JP2018552872A external-priority patent/JP7240176B2/ja
Application filed filed Critical
Publication of JP2023081949A publication Critical patent/JP2023081949A/ja
Publication of JP2023081949A5 publication Critical patent/JP2023081949A5/ja
Application granted granted Critical
Publication of JP7577149B2 publication Critical patent/JP7577149B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023032695A 2016-04-08 2023-03-03 T細胞受容体 Active JP7577149B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB201606177 2016-04-08
GB1606177.2 2016-04-08
JP2018552872A JP7240176B2 (ja) 2016-04-08 2017-04-10 T細胞受容体
PCT/EP2017/058580 WO2017174824A1 (en) 2016-04-08 2017-04-10 T cell receptors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018552872A Division JP7240176B2 (ja) 2016-04-08 2017-04-10 T細胞受容体

Publications (3)

Publication Number Publication Date
JP2023081949A JP2023081949A (ja) 2023-06-13
JP2023081949A5 true JP2023081949A5 (cg-RX-API-DMAC7.html) 2023-10-16
JP7577149B2 JP7577149B2 (ja) 2024-11-01

Family

ID=58701592

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018552872A Active JP7240176B2 (ja) 2016-04-08 2017-04-10 T細胞受容体
JP2023032695A Active JP7577149B2 (ja) 2016-04-08 2023-03-03 T細胞受容体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2018552872A Active JP7240176B2 (ja) 2016-04-08 2017-04-10 T細胞受容体

Country Status (25)

Country Link
US (5) US11286289B2 (cg-RX-API-DMAC7.html)
EP (2) EP3988565B1 (cg-RX-API-DMAC7.html)
JP (2) JP7240176B2 (cg-RX-API-DMAC7.html)
KR (2) KR102523449B1 (cg-RX-API-DMAC7.html)
CN (2) CN109476725B (cg-RX-API-DMAC7.html)
AU (2) AU2017248122B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018070625A2 (cg-RX-API-DMAC7.html)
CA (1) CA3020058A1 (cg-RX-API-DMAC7.html)
CY (1) CY1124664T1 (cg-RX-API-DMAC7.html)
DK (1) DK3440106T3 (cg-RX-API-DMAC7.html)
ES (1) ES2891321T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20211493T1 (cg-RX-API-DMAC7.html)
HU (1) HUE056433T2 (cg-RX-API-DMAC7.html)
IL (1) IL262128B2 (cg-RX-API-DMAC7.html)
LT (1) LT3440106T (cg-RX-API-DMAC7.html)
MX (2) MX395611B (cg-RX-API-DMAC7.html)
PL (1) PL3440106T3 (cg-RX-API-DMAC7.html)
PT (1) PT3440106T (cg-RX-API-DMAC7.html)
RS (1) RS62623B1 (cg-RX-API-DMAC7.html)
RU (1) RU2018138838A (cg-RX-API-DMAC7.html)
SG (1) SG11201808751SA (cg-RX-API-DMAC7.html)
SI (1) SI3440106T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202100564T1 (cg-RX-API-DMAC7.html)
WO (1) WO2017174824A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA201806866B (cg-RX-API-DMAC7.html)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA50819A (fr) 2014-12-23 2021-04-07 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
KR20190065189A (ko) 2016-04-08 2019-06-11 어댑티뮨 리미티드 T 세포 수용체
MX2018012265A (es) * 2016-04-08 2019-02-07 Adaptimmune Ltd Receptores de celulas t.
MX395611B (es) 2016-04-08 2025-03-25 Adaptimmune Ltd Receptores de celulas t.
WO2019069125A1 (en) 2017-10-06 2019-04-11 Oslo Universitetssykehus Hf CHIMERIC ANTIGEN RECEPTORS
CN109777778B (zh) * 2017-11-14 2023-07-18 中国科学院广州生物医药与健康研究院 一种基因改造的γδT细胞
GB201803750D0 (en) 2018-03-08 2018-04-25 Immunocore Ltd Method
GB201819540D0 (en) 2018-11-30 2019-01-16 Adaptimmune Ltd T cell modification
EP3714941A1 (en) * 2019-03-27 2020-09-30 Medigene Immunotherapies GmbH Mage-a4 tcrs
MA55911A (fr) * 2019-05-08 2022-03-16 2Seventy Bio Inc Lymphocytes t génétiquement modifiés
MX2021015946A (es) * 2019-06-18 2022-04-18 Regeneron Pharma Receptores de linfocitos t de mage-a4 y métodos de uso de estos.
CN114245807B (zh) 2019-06-25 2025-05-02 吉利德科学公司 Flt3l-fc融合蛋白和使用方法
BR112022001194A2 (pt) 2019-07-24 2022-06-07 Regeneron Pharma Receptores de antígeno quimérico com especificidade de mage a4 e usos dos mesmos
CN114555791B (zh) 2019-08-13 2026-07-14 伦敦国王学院 Il-1超家族时空限制性活性细胞因子铠装的免疫应答细胞
CN114828965B (zh) 2019-12-18 2025-09-05 豪夫迈·罗氏有限公司 与hla-a2/mage-a4结合的抗体
AU2021208433A1 (en) * 2020-01-14 2022-07-14 Uswm Ct, Llc Method of treatment of cancer or tumour
TWI890283B (zh) 2020-02-14 2025-07-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
GB202006903D0 (en) * 2020-05-11 2020-06-24 Adaptimmune Ltd Modified iPSCs
WO2021236638A1 (en) 2020-05-19 2021-11-25 Amgen Inc. Mageb2 binding constructs
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
EP4304726A1 (en) * 2021-03-09 2024-01-17 CDR-Life AG Mage-a4 peptide-mhc antigen binding proteins
US12435444B2 (en) 2021-03-09 2025-10-07 Cdr-Life Ag Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
EP4091627A1 (en) 2021-05-21 2022-11-23 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Tcr constructs specific for magea4-derived epitopes
CA3236237A1 (en) * 2021-10-25 2023-05-04 Board Of Regents, The University Of Texas System Peptides and engineered t cell receptors targeting mage-a4 antigen and methods of use
EP4423078A1 (en) 2021-10-28 2024-09-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
PE20241186A1 (es) 2021-10-29 2024-06-03 Gilead Sciences Inc Compuestos de cd73
US20240124412A1 (en) 2021-12-22 2024-04-18 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CN118488948A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
CA3248911A1 (en) 2022-01-28 2023-08-03 Gilead Sciences, Inc. POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE 7 INHIBITORS
PL4245756T3 (pl) 2022-03-17 2025-02-17 Gilead Sciences, Inc. Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania
CN116836261A (zh) * 2022-03-24 2023-10-03 香雪生命科学技术(广东)有限公司 一种识别mage-a4抗原的高亲和力tcr及其序列和应用
GB202205572D0 (en) 2022-04-14 2022-06-01 Adaptimmune Ltd Engineered T cells
EP4511127A1 (en) 2022-04-21 2025-02-26 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
EP4587046A1 (en) 2022-09-14 2025-07-23 CDR-Life AG Mage-a4 peptide dual t cell engagers
AU2023241306B2 (en) * 2022-10-05 2024-10-03 Tscan Therapeutics, Inc. Prame immunogenic peptides, binding proteins recognizing prame immunogenic peptides, and uses thereof
CN120302989A (zh) * 2022-10-05 2025-07-11 帝斯肯医疗公司 Magea1免疫原性肽、识别magea1免疫原性肽的结合蛋白和其用途
EP4638436A1 (en) 2022-12-22 2025-10-29 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2024215754A1 (en) 2023-04-11 2024-10-17 Gilead Sciences, Inc. Kras modulating compounds
PE20260121A1 (es) 2023-04-21 2026-01-16 Gilead Sciences Inc Inhibidores de prmt5 y usos de los mismos
JP2026522894A (ja) 2023-06-30 2026-07-09 ギリアード サイエンシーズ, インコーポレイテッド Kras調節化合物
AU2024297978A1 (en) 2023-07-26 2026-02-05 Gilead Sciences, Inc. Parp7 inhibitors
CN121568935A (zh) 2023-07-26 2026-02-24 吉利德科学公司 Parp7抑制剂
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
EP4774280A1 (en) 2023-09-08 2026-07-15 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025096589A1 (en) 2023-11-03 2025-05-08 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20260098049A1 (en) 2024-08-12 2026-04-09 Gilead Sciences, Inc. Kras modulating compounds
US20260130893A1 (en) 2024-10-21 2026-05-14 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2026135172A1 (ko) * 2024-12-17 2026-06-25 중앙대학교 산학협력단 Magea4-fc 형질전환 식물체의 제조방법
WO2026136515A1 (en) 2024-12-19 2026-06-25 Gilead Sciences, Inc. Parp7 inhibitors

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0869943A1 (en) * 1995-12-08 1998-10-14 Smithkline Beecham Plc Monocyclic beta-lactame derivatives for treatment of atherosclerosis
US7521197B2 (en) 1998-06-05 2009-04-21 Alexis Biotech Limited Method for producing cytotoxic T-cells
AU5992999A (en) * 1998-10-02 2000-04-26 Ludwig Institute For Cancer Research Tumor antigens and ctl clones isolated by a novel procedure
US7157091B1 (en) * 1999-06-18 2007-01-02 Ludwig Institute For Cancer Research MAGE-A1 peptides presented by HLA class II molecules
US6867283B2 (en) 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
US7049413B2 (en) 2001-05-18 2006-05-23 Ludwig Institute For Cancer Research MAGE-A3 peptides presented by HLA class II molecules
PT1421115E (pt) 2001-08-31 2005-07-29 Avidex Ltd Receptor de celulas t soluvel
KR100467944B1 (ko) 2002-07-15 2005-01-24 엘지.필립스 엘시디 주식회사 반사투과형 액정표시장치 및 그의 제조방법
RU2355703C2 (ru) 2002-10-09 2009-05-20 Медиджен Лимитед Одноцепочечные рекомбинантные т-клеточные рецепторы
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
CN101287831B (zh) * 2005-09-13 2013-05-15 国立大学法人三重大学 T细胞受体和编码该受体的核酸
WO2010114129A1 (ja) * 2009-04-03 2010-10-07 国立大学法人愛媛大学 T細胞レセプター及び該レセプターをコードする核酸
ES2635335T3 (es) * 2010-09-20 2017-10-03 Biontech Cell & Gene Therapies Gmbh Receptores de células T específicos de antígeno y epítopos de células T
WO2012054825A1 (en) 2010-10-22 2012-04-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mage-a3 t cell receptors and related materials and methods of use
SI2755997T1 (sl) 2011-09-15 2018-11-30 The United States of America, as represented by Secretary, Department of Health and Human Services, Office of Technology Transfer, National Institutes of Health T-celični receptorji, ki prepoznajo HLA-A1- ali HLA-CW7-omejeni mage
WO2013041865A1 (en) * 2011-09-22 2013-03-28 Immunocore Limited T cell receptors
SG11201400521PA (en) * 2011-10-14 2014-08-28 Teva Pharmaceuticals Australia Pty Ltd ANTIBODIES TO CD1d
KR20150131208A (ko) 2013-03-13 2015-11-24 이미지냅 인코포레이티드 Cd8에의 항원 결합 구조체들
GB201313377D0 (en) * 2013-07-26 2013-09-11 Adaptimmune Ltd T cell receptors
GB201417803D0 (en) 2014-10-08 2014-11-19 Adaptimmune Ltd T cell receptors
KR102349677B1 (ko) 2015-05-28 2022-01-12 카이트 파마 인코포레이티드 T 세포 요법을 위해 환자를 컨디셔닝하는 방법
IL292504B2 (en) 2015-10-20 2024-01-01 Kite Pharma Inc -methods of preparing t cells for t cell therapy
CN106749620B (zh) 2016-03-29 2020-09-25 广东香雪精准医疗技术有限公司 识别mage-a1抗原短肽的t细胞受体
MX395611B (es) 2016-04-08 2025-03-25 Adaptimmune Ltd Receptores de celulas t.
MX2018012265A (es) 2016-04-08 2019-02-07 Adaptimmune Ltd Receptores de celulas t.
KR20190065189A (ko) 2016-04-08 2019-06-11 어댑티뮨 리미티드 T 세포 수용체
GB201616238D0 (en) 2016-09-23 2016-11-09 Adaptimmune Ltd Modified T cells
AU2018234830B2 (en) 2017-03-15 2023-03-02 Fred Hutchinson Cancer Center High affinity MAGE-A1-specific TCRs and uses thereof
GB201713078D0 (en) 2017-08-15 2017-09-27 Adaptimmune Ltd T Cell Modification
US20210317184A1 (en) 2018-09-05 2021-10-14 GlaxoSmithKline Intellectual Property Devolopment Limited T cell modification

Similar Documents

Publication Publication Date Title
JP2022122913A5 (cg-RX-API-DMAC7.html)
JP2022153399A5 (cg-RX-API-DMAC7.html)
JP2022502056A5 (cg-RX-API-DMAC7.html)
HRP20230542T1 (hr) T stanični receptori
HRP20190472T1 (hr) Klaudin-6 specifični imunoreceptori i t-stanični epitopi
JP2024530487A5 (cg-RX-API-DMAC7.html)
IL262128B2 (en) T cell receptors
HRP20221021T1 (hr) T stanični receptori specifični za kompleks tumorskog antigena ny-eso-1 sa hla-a*02
JP2022513420A5 (cg-RX-API-DMAC7.html)
JP2019508013A5 (cg-RX-API-DMAC7.html)
JP2022514255A5 (cg-RX-API-DMAC7.html)
JP2012500001A5 (cg-RX-API-DMAC7.html)
US20260015395A1 (en) Molecular guide system peptides and uses thereof
JP2021531834A5 (cg-RX-API-DMAC7.html)
JP2021512107A5 (cg-RX-API-DMAC7.html)
JP2023500338A5 (cg-RX-API-DMAC7.html)
WO2022221746A1 (en) Il-2 based constructs
JP2025530888A5 (cg-RX-API-DMAC7.html)
JPWO2018026018A1 (ja) T細胞受容体の認識機構を用いたがん又は感染症の治療及び診断
JP2021525067A5 (cg-RX-API-DMAC7.html)
JP2022035920A5 (cg-RX-API-DMAC7.html)
JP2022547809A5 (cg-RX-API-DMAC7.html)
JP2022554353A5 (cg-RX-API-DMAC7.html)
JP2022553940A5 (cg-RX-API-DMAC7.html)
JP2023526416A5 (cg-RX-API-DMAC7.html)